Q-omics provides the consensus-scored GPAT2P1 profile across patient tissues and cancer cell-line models. GPAT2P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, GPAT2P1 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, GPAT2P1 RNA expression shows 8,937 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight OV, THCA, and THYM as cancer lineages where GPAT2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPAT2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPAT2P1 survival associations across molecular data types. GPAT2P1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPAT2P1 RNA expression–survival associations across cancer types. High GPAT2P1 expression shows unfavorable associations in LUSC and LGG, but favorable associations in OV, SKCM, PAAD and CESC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify OV as the clearest survival context for GPAT2P1 RNA expression.
This table summarizes GPAT2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GPAT2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPAT2P1 shows lower tumor expression in THCA, BRCA, LUSC and COAD and higher tumor expression in LUAD and LIHC. The THCA box plot shows higher GPAT2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.112, t-test p = .001).
This table shows molecular features associated with GPAT2P1 in patient tissues and cancer cell lines. In patient samples, GPAT2P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
